In pre-clinical studies, lirafugratinib inhibited FGFR2 phosphorylation, downstream signalling and proliferation of FGFR2-amplified SNU-16 GC cells in vitro and in vivo, and notably induced significantly less hyperphosphatemia compared to pan-FGFR inhibitors [90]. This evidence concerns the gene FGFR2 and gastric cancer.